Tether attachment for mitral valve

Information

  • Patent Grant
  • 12144727
  • Patent Number
    12,144,727
  • Date Filed
    Monday, July 12, 2021
    3 years ago
  • Date Issued
    Tuesday, November 19, 2024
    a month ago
Abstract
A prosthetic mitral valve with improved blood flow to the left ventricular outflow tract. The prosthetic mitral valve includes an expandable outer stent having an atrial end and a ventricular end, and an expandable inner stent attached to and at least partially positioned within the outer stent. The inner stent has an inflow end, an outflow end and a tether connector securing a tether. A valve assembly including a cuff and a plurality of leaflets may be disposed within the inner stent. The tether connector is positioned at the inflow end of the inner stent so as to shorten the overall length of the prosthetic valve.
Description
BACKGROUND OF THE DISCLOSURE

The present disclosure relates to collapsible and expandable prosthetic heart valves, and more particularly, to apparatus and methods for stabilizing a collapsible and expandable prosthetic heart valve within a native annulus of a patient.


Prosthetic heart valves that are collapsible to a relatively small circumferential size can be delivered into a patient less invasively than valves that are not collapsible. For example, a collapsible and expandable valve may be delivered into a patient via a tube-like delivery apparatus such as a catheter, a trocar, a laparoscopic instrument, or the like. This collapsibility can avoid the need for a more invasive procedure such as full open-chest, open-heart surgery.


Collapsible and expandable prosthetic heart valves typically take the form of a valve structure mounted on a stent. There are two types of stents on which the valve structures are ordinarily mounted: a self-expanding stent and a balloon-expandable stent. To place such valves into a delivery apparatus and ultimately into a patient, the valve must first be collapsed to reduce its circumferential size.


When a collapsed prosthetic valve has reached the desired implant site in the patient (e.g., at or near the native annulus of the patient's heart valve that is to be repaired by the prosthetic valve), the prosthetic valve can be deployed or released from the delivery apparatus and expanded to its full operating size. For balloon-expandable valves, this generally involves releasing the entire valve, assuring its proper location, and then expanding a balloon positioned within the valve stent. For self-expanding valves, on the other hand, the stent automatically expands as the stent is withdrawn from the delivery apparatus.


The clinical success of collapsible and expandable heart valves is dependent, in part, on the anchoring of the valve within the native valve annulus. Self-expanding valves typically rely on the radial force exerted by expanding the stent against the native valve annulus to anchor the prosthetic heart valve. However, if the radial force is too high, the heart tissue may be damaged. If, instead, the radial force is too low, the heart valve may move from its deployed position and/or migrate from the native valve annulus, for example, into the left ventricle.


Movement of the prosthetic heart valve may result in the leakage of blood between the prosthetic heart valve and the native valve annulus. This phenomenon is commonly referred to as paravalvular leakage. In mitral valves, paravalvular leakage enables blood to flow from the left ventricle back into the left atrium during ventricular systole, resulting in reduced cardiac efficiency and strain on the heart muscle.


Anchoring prosthetic heart valves within the native valve annulus of a patient, especially within the native mitral valve annulus, can be difficult. For instance, the native mitral valve annulus has reduced calcification or plaque compared to the native aortic valve annulus, for example, which can make for a less stable surface to anchor the prosthetic heart valve. For this reason, collapsible and expandable prosthetic mitral valves often include additional anchoring features such as a tether. The tether is commonly secured to an apical pad placed at the apex of the heart to anchor the prosthetic heart valve in position within the native valve annulus of the patient.


Despite the improvements that have been made to anchoring collapsible and expandable prosthetic heart valves, shortcomings remain. For example, to accommodate the tether, the prosthetic heart valve often extends at least partially into the ventricle, which can impede blood flow to the Left Ventricular Outflow Tract (LVOT).


BRIEF SUMMARY OF THE DISCLOSURE

In accordance with a first aspect of the present disclosure, a collapsible and expandable prosthetic heart valve having a low-profile is provided. Among other advantages, the prosthetic heart valve is designed to be securely anchored within the native mitral valve annulus without projecting into the ventricle. As a result, the prosthetic heart valve disclosed herein minimizes the obstruction of blood flow to the LVOT.


One embodiment of the prosthetic heart valve includes a prosthetic heart valve having an expandable stent with an inflow end and an outflow end, a valve assembly disposed within the stent including a cuff and a plurality of leaflets, a tether connector positioned between the inflow end and the valve assembly and a tether secured to the tether connector.


A method of implanting a prosthetic heart valve within a native heart valve annulus is provided herein and includes delivering a delivery device to a target site adjacent to a native valve annulus while the delivery device holds a prosthetic heart valve including a stent, a valve assembly disposed within the stent and a tether attached to the stent; deploying the prosthetic heart valve from the delivery device within the native valve annulus; creating a passage through the wall of the heart; extending the tether through the valve assembly and through the passage to a location outside the heart; attaching an apical pad to the tether; tensioning the tether; and securing the apical pad against an external surface of the heart.





BRIEF DESCRIPTION OF THE DRAWINGS

Various embodiments of the present disclosure are described herein with reference to the drawings, wherein:



FIG. 1 is a highly schematic cutaway view of the human heart, showing two approaches for delivering a prosthetic mitral valve to an implantation location;



FIG. 2 is a highly schematic representation of a native mitral valve and associated cardiac structures;



FIG. 3 is a highly schematic longitudinal cross-section of a prosthetic mitral valve according to an embodiment of the present disclosure;



FIG. 4 is a side elevational view of an inner stent of the prosthetic mitral valve of FIG. 3;



FIG. 5 is a side elevational view of an outer stent of the prosthetic mitral valve of FIG. 3;



FIG. 6 is a highly schematic partial side view of a delivery catheter for deploying the prosthetic mitral valve of FIG. 3;



FIG. 7A is a highly schematic side elevational view illustrating deployment of the prosthetic mitral valve of FIG. 3 within the native mitral valve annulus; and



FIG. 7B is a highly schematic side elevational view illustrating retrieval of the prosthetic mitral valve of FIG. 3 from the native mitral valve annulus.





DETAILED DESCRIPTION

Blood flows through the mitral valve from the left atrium to the left ventricle. As used herein in connection with a prosthetic heart valve, the term “inflow end” refers to the end of the heart valve through which blood enters when the valve is functioning as intended, and the term “outflow end” refers to the end of the heart valve through which blood exits when the valve is functioning as intended. Also as used herein, the terms “substantially,” “generally,” “approximately,” and “about” are intended to mean that slight deviations from absolute are included within the scope of the term so modified.



FIG. 1 is a schematic cutaway representation of a human heart H. The human heart includes two atria and two ventricles: right atrium RA and left atrium LA, and right ventricle RV and left ventricle LV. Heart H further includes aorta A, aortic arch AA and left ventricular outflow tract LVOT. Disposed between the left atrium and the left ventricle is mitral valve MV. The mitral valve, also known as the bicuspid valve or left atrioventricular valve, is a dual-flap that opens as a result of increased pressure in left atrium LA as it fills with blood. As atrial pressure increases above that in left ventricle LV, mitral valve MV opens and blood flows into the left ventricle. When left ventricle LV contracts during ventricular systole, blood is pushed from the left ventricle, through left ventricular outflow tract LVOT and into aorta A. Blood flows through heart H in the direction shown by arrows “B”.


A dashed arrow, labeled “TA”, indicates a transapical approach of implanting a prosthetic heart valve, in this case to replace the mitral valve. In the transapical approach, a small incision is made between the ribs of the patient and into the apex of left ventricle LV to deliver the prosthetic heart valve to the target site. A second dashed arrow, labeled “TS”, indicates a transseptal approach of implanting a prosthetic heart valve in which the delivery device is inserted into the femoral vein, passed through the iliac vein and the superior vena cava into the right atrium RA, and then through the atrial septum into the left atrium LA for deployment of the valve. Other approaches for implanting a prosthetic heart valve are also possible and may be used to implant the collapsible prosthetic heart valve described in the present disclosure.



FIG. 2 is a more detailed schematic representation of native mitral valve MV and its associated structures. As previously noted, mitral valve MV includes two flaps or leaflets, posterior leaflet PL and anterior leaflet AL, disposed between left atrium LA and left ventricle LV. Cord-like tendons, known as chordae-tendineae CT, connect the two leaflets to the medial and lateral papillary muscles P. During atrial systole, blood flows from higher pressure in left atrium LA to lower pressure in left ventricle LV. When left ventricle LV contracts during ventricular systole, the increased blood pressure in the chamber pushes the posterior and anterior leaflets to close, preventing the backflow of blood into left atrium LA. Since the blood pressure in left atrium LA is much lower than that in left ventricle LV, the leaflets attempt to evert to low pressure regions. Chordae tendineae CT prevent the eversion by becoming tense, thus pulling on the leaflets and holding them in the closed position.



FIG. 3 is highly schematic longitudinal cross-section of a collapsible and expandable prosthetic heart valve 10 according to an embodiment of the present disclosure. For balloon-expandable variants, prosthetic heart valve 10 may be expandable, but not collapsible, or not readily collapsible, once expanded. When used to replace native mitral valve MV (shown in FIG. 1), prosthetic valve 10 may have a low profile so as minimize any interference with the heart's electrical conduction system pathways, atrial function or blood flow to the left ventricular outflow tract LVOT (shown in FIG. 1).


Prosthetic heart valve 10 includes an inner stent 12 securing a valve assembly 14, an outer stent 16 attached to and disposed around the inner stent, and a tether 18 configured to be secured to an apical pad 20. Both the inner stent 12 and the outer stent 16 may be formed from biocompatible materials that are capable of self-expansion, for example, shape-memory alloys such as nitinol. Alternatively, inner stent 12 and/or outer stent 16 may be balloon expandable or expandable by another force exerted radially outward on the stent. When expanded, outer stent 16 may exert an outwardly directed radial force against the native valve annulus that assists in anchoring inner stent 12 and valve assembly 14 within the native annulus.


Referring to FIG. 4, inner stent 12 extends along a longitudinal axis between an inflow end 22 and an outflow end 24. In one example, inner stent 12 is formed by laser cutting a predetermined pattern into a metallic tube, such as a nitinol tube, to form three portions: a body portion 26, a strut portion 28 and a tether connector 30 that secures tether 18 (shown in FIG. 3). As shown in FIG. 4, body portion 26 is positioned at the outflow end 24 of inner stent 12, tether connector 30 is positioned at the inflow end 22 of the inner stent and strut portion 28 extends between the body portion and the tether connector. Strut portion 28 may include, for example, six struts that extend radially inward from body portion 26 to tether connector 30. When inner stent 12 is expanded, tether connector 30 and, in turn, tether 18 are positioned along the longitudinal axis of the inner stent to centrally anchor prosthetic heart valve 10. Body portion 26 may include six longitudinal posts 32 having one or more bores 34 for securing valve assembly 14 to the inner stent 12 by one or more sutures.


With additional reference to FIG. 3, valve assembly 14 may be secured to inner stent 12 by suturing the valve assembly to longitudinal posts 32. Valve assembly 14 includes a cuff 36 and a plurality of leaflets 38 that open and close collectively to function as a one-way valve. Cuff 36 and leaflets 38 may be wholly or partly formed of any suitable biological material, such as bovine or porcine pericardium, or biocompatible polymer, such as polytetrafluorethylene (PTFE), urethanes and the like. The bores 34 of longitudinal posts 32 facilitate the suturing of the leaflet commissure to the body portion 26 of inner stent 12.


Turning now to FIG. 5, outer stent 16 extends between an atrial end 40 and a ventricular end 42 along the same longitudinal axis as inner stent 12. Outer stent 16 may include a plurality of struts 44 that form cells 46 extending about the outer stent in one or more annular rows. In one example, outer stent 16 is formed by laser cutting a predetermined pattern into a metallic tube, such as a self-expanding nitinol tube. Cells 46 may be substantially the same size around the perimeter of stent 16 and along the length of the stent. Alternatively, cells 46 near the atrial end 40 of outer stent 16 may be larger than the cells near the ventricular end 42. A plurality of attachment features 48 may lie at the intersections of the struts 44 that form the cells 46 at the ventricular end 42 of outer stent 16. Attachment features 48 may include an eyelet that facilitates the suturing of outer stent 16 to the longitudinal posts 32 of inner stent 12, thereby securing the inner and outer stents together. In one example, each attachment feature 48 may be sutured to a single bore 34 of longitudinal post 32, proximate to the outflow end 24 of inner stent 12. With further reference to FIG. 3, a pair of diametrically opposed retaining loops 50 may be provided on the ventricular end 42 of outer stent 16. Each retaining loop 50 is designed to receive a looped suture 52 (shown in FIGS. 7A and 7B) to cinch the ventricular end 42 of outer stent 16 toward the longitudinal axis if repositioning or complete retrieval of prosthetic heart valve 10 is required after the prosthetic heart valve has been fully deployed.


When outer stent 16 is expanded, the struts 44 forming the cells 46 in the annular row of cells adjacent the atrial end 40 of the outer stent may bend about the midsections of the cells (e.g., in a direction generally orthogonal to the longitudinal axis) such that the upper apexes of the cells extend radially outward relative to the midsections of the cells and collectively form an atrial flange. The flange is designed to protrude into the left atrium LA and engage an upper surface of the native mitral valve annulus when prosthetic valve 10 is disposed within the native mitral valve MV, thereby preventing the mitral valve from migrating into left ventricle LV. Prosthetic heart valve 10 is anchored within the native mitral valve annulus by the radial force exerted by outer stent 16 against the native annulus, the flange engaging the atrial surface of the native valve annulus and the tether anchored to the ventricular wall of the heart. As is schematically shown in FIG. 3, the flange is the only portion of prosthetic heart valve 10 that is designed to extend out from the native mitral valve annulus. Put another way, inner stent 12 and outer stent 16 are designed with a low-profile so as to not extend into left ventricle LV. In this manner, prosthetic heart valve 10 does not interfere with blood flow to the left ventricular outflow tract LVOT. The low-profile design is possible, in part, because tether connector 30 is positioned upstream of valve assembly 14, for example, adjacent the atrial end 40 of outer stent 16. When prosthetic heart valve 10 is implanted within the native mitral valve annulus and tether 18 is anchored to the apex of the heart, the tether extends through valve assembly 14 from tether connector 30 to apical pad 20. During ventricular systole, leaflets 38 close around tether 18.


Due to the low-profile of prosthetic heart valve 10, Systolic Anterior Motion (SAM) prevention features may optionally be provided, for example, on outer stent 16. SAM (e.g., the displacement of the free edge of native anterior leaflet AL toward left ventricular outflow tract LVOT) can result in severe left ventricular outflow tract LVOT obstruction and/or mitral regurgitation. To prevent the occurrence of SAM, or at least significantly reduce its likelihood, a ring 54 may be positioned on an anterior side of outer stent 16. A cord 56 attached at one end to ring 54 may be inserted through native anterior leaflet AL (shown in FIGS. 1 and 2) to secure the native anterior leaflet to prosthetic heart valve 10. In one embodiment, ring 54 may extend from one of attachment features 48 positioned on an anterior side of outer stent 16. Ring 54 may alternatively lie at an intersection of two struts 44 that form a cell 46 at the ventricular end 42 and anterior side of outer stent 16.


In a preferred embodiment, prosthetic heart valve 10 may include an inner skirt 58, an outer skirt 60 and a cover 62. Outer skirt 60 may be disposed about the abluminal surface of outer stent 16 and may be formed of a polyester fabric that promotes tissue ingrowth. Inner skirt 58 may be disposed about the luminal surface of outer stent 16 and may be formed of any suitable biological material, such as bovine or porcine pericardium, or any suitable biocompatible polymer, such as PTFE, urethanes or similar materials. When prosthetic heart valve 10 is secured within the native mitral valve annulus, inner skirt 58 acts in combination with outer skirt 60 to prevent mitral regurgitation, or the flow of blood between the prosthetic heart valve 10 and the native mitral valve annulus. In one embodiment, inner skirt 58 and outer skirt 60 extend only between the atrial end 40 of outer stent 16 and attachment features 48 to facilitate the suturing of the outer stent to inner stent 12. Cover 62 may be attached from the atrial end 40 of outer stent 16 to the junction of body portion 26 and strut portion 28 of inner stent 12 such that the cover extends across a gap defined between the inner stent and the outer stent, forming a pocket 64 underneath the cover and between the inner and outer stents. Cover 62 may be formed from a porous polyester mesh material. The pores of the mesh material are preferably of a size that allows antegrade blood to flow into pocket 64, but prevents coagulated blood, or thrombosis, from leaving the pocket.


Prosthetic heart valve 10 may be used to repair a malfunctioning native heart valve, such as a native mitral valve, or a previously implanted and malfunctioning prosthetic heart valve. Although prosthetic heart valve 10 is described herein as repairing a native mitral valve, it will be appreciated that the prosthetic heart valve may be used to repair other cardiac valves such as the aortic valve. Once prosthetic heart valve 10 has been properly positioned within the native mitral valve annulus of the patient, it works as a one-way valve, allowing blood to flow into left ventricle LV, and preventing blood from returning to left atrium LA.



FIG. 6 is a partial, schematic illustration of a delivery device 100 for implanting the prosthetic heart valve, and if necessary, repositioning or removing it from the native mitral annulus of the patient after the prosthetic heart valve has been deployed from the delivery device. While delivery device 100 is described herein as delivering prosthetic heart valve 10 to the native mitral valve annulus using a transapical approach, it will be appreciated that the prosthetic heart valve may alternatively be delivered using a transseptal or another approach.


Delivery device 100 includes a handle (not shown) connected to a delivery tube 102 having a lumen 104 therethrough, an outer dilator 106 disposed within the lumen of the delivery tube and an inner dilator 108 disposed within the lumen of the outer dilator. The handle may include one or more actuators, such as rotatable knobs, linear slides, pull handles, levers, or buttons, for controlling the operation of delivery device 100. Delivery tube 102 extends from a leading end 110 to a trailing end (not shown) at which the delivery tube is operably connected to the handle. Delivery device 100 may be any tube-like delivery device, such as a catheter, a trocar, a laparoscopic instrument, or the like, configured to house prosthetic heart valve 10 as the delivery device is advanced toward the native mitral valve annulus.


In one embodiment, delivery tube 102 may be mounted on a carriage (not shown) that is slidably mounted within the handle. The carriage is thus configured to retract delivery tube 102 to deploy prosthetic heart valve 10 from the leading end 110 of the delivery tube. By way of example, the carriage may be coupled to a first actuator, which may be a rotatable knob that precisely controls movement of delivery tube 102, and/or a linearly translatable actuator such as a slide that quickly translates the carriage and, in turn, the delivery tube.


Inner dilator 108 may be rotatably disposed within the lumen of outer dilator 106. Rotation of inner dilator 108 may be controlled by a second actuator disposed on the handle. The second actuator may, for example, be a manually operated rotatable knob or a button that activates a motorized rotation mechanism. A pair of suture receiving clips or another suture attachment mechanism (not shown) may be provided adjacent the leading end of inner dilator 108. Outer dilator 106 may have a pair of diametrically opposed holes 112 at its leading end and proximate the suture clips of inner dilator 108. In this manner, sutures 52, attached to the retaining loops 50 of prosthetic heart valve 10, may be threaded through holes 112 of outer dilator 106 and secured to the suture clips of inner dilator 108 as shown in FIGS. 7A and 7B. Both inner dilator 108 and outer dilator 106 may have open leading ends, with the inner dilator also having a lumen extending from its leading end to its trailing end for receiving the tether 18 of prosthetic heart valve 10.


The use of delivery device 100 to deliver and, if necessary, reposition or retrieve prosthetic heart valve 10, will now be described with reference to FIGS. 7A and 7B. With delivery tube 102 in a retracted condition to expose the dilators, a physician may initially couple prosthetic heart valve 10 to delivery device 100 by inserting suture 52 through and around the retaining loops 50 of outer stent 16, through the holes 112 of outer dilator 106 and into engagement with the suture clips of inner dilator 108. Prosthetic heart valve 10 may then be collapsed and delivery tube 102 may be extended to load the heart valve within delivery device 100 such that the prosthetic heart valve is positioned between dilators 106, 108 and the leading end 110 of the delivery tube. Tether 18 may be fed from its connection to the prosthetic heart valve, through the open end and lumen of inner dilator 108 and out from the trailing end of the inner dilator such that the free end of the tether may be engaged with a tether retention mechanism, such as a tether pin, located on the handle of the delivery device. The amount of clearance between tether 18 and the inner wall of inner dilator 108 is such that the tether is not affected by the rotation of the inner dilator.


After an incision has been made between the ribs of the patient and into the apex of the heart, delivery device 100 may be percutaneously introduced into the patient using a transapical approach and delivered to an implant site adjacent the native mitral valve annulus. Once delivery device 100 has reached the target site, the first actuator may be actuated to retract delivery tube 102. Actuation of the first actuator will unsheathe prosthetic heart valve 10, allowing outer stent 16 to expand from the collapsed condition and engage the native valve annulus, while also allowing inner stent 12 to expand from the collapsed condition to the expanded condition within the outer stent. After the inner stent 12 and the outer stent 16 have been expanded, a physician may determine whether prosthetic heart valve 10 has restored proper blood flow through the native mitral valve. More particularly, the physician may determine: 1) whether valve assembly 14 is functioning properly; and 2) whether the prosthetic heart valve 10 has been properly seated within the native valve annulus to form a seal between the prosthetic heart valve and the native mitral valve annulus.


In the event that the physician determines that the valve assembly 14 is malfunctioning or that prosthetic heart valve 10 is positioned incorrectly within the native mitral annulus, the physician may recapture the prosthetic heart valve. To recapture prosthetic heart valve 10, the physician may actuate the second actuator which causes inner dilator 108 to rotate about its axis relative to outer dilator 106 and delivery tube 102. Rotation of inner dilator 108 results in sutures 52 wrapping about the inner dilator and forcing the ventricular end 42 of outer stent 16 to collapse toward the longitudinal axis to a diameter capable of being inserted into the leading end 110 of delivery tube 102, for example, a diameter of equal to or less than approximately 36 French. Collapsing the ventricular end 42 of outer stent 16 similarly collapses the outflow end 24 of inner stent 12. With the ventricular end 42 of outer stent 16 and the outflow end of inner stent 12 collapsed, tether 18 may be disengaged from the tether retention mechanism and retracted toward the trailing end of delivery device 100 to pull the outer stent, and with it inner stent 12, within delivery tube 102. If valve assembly 14 was working as intended, but prosthetic heart valve 10 was mispositioned within the native mitral valve annulus, the physician may only need to partially collapse the prosthetic heart valve within delivery tube 102 before repositioning the delivery tube with respect to the native mitral annulus and redeploying the prosthetic heart valve as previously described. Alternatively, if valve assembly 14 was malfunctioning, prosthetic heart valve 10 may be completely recaptured and removed from the patient. The physician may then repeat the procedure described above with a different prosthetic heart valve 10.


Once the physician has confirmed that prosthetic heart valve 10 has been properly positioned within the native annulus of the patient, sutures 52 may be cut or otherwise disengaged from inner dilator 108. Delivery device 100 may then be removed from the patient.


In some instances, the physician may find it desirable to secure the native anterior leaflet AL of native mitral valve MV to the outer stent 16 of prosthetic mitral valve 10 to prevent SAM. Using a clamp (not shown) and a needle (not shown), or another piercing tool, the physician may hold the anterior leaflet while piercing a hole through the leaflet. Cord 56 may then be inserted through the hole and tied to the native anterior leaflet to secure the native leaflet to prosthetic heart valve 10.


Once the prosthetic heart valve 10 has been properly positioned in the native valve annulus, the physician may pull tether 18 through the puncture at the apex of the heart so that the tether extends out from the left ventricle LV of the heart. Apical pad 20 may then be inserted through the incision between the ribs of the patient and placed against an external surface of the heart before tether 18 is tensioned and secured to the apical pad. With prosthetic heart valve 10 properly positioned and anchored within the native mitral valve annulus of a patient, the prosthetic heart valve may work as a one-way valve to restore proper function of the heart valve by allowing blood to flow in one direction (e.g., from the left atrium to the left ventricle) while preventing blood from flowing in the opposite direction.


Although the invention herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the spirit and scope of the present invention as defined by the appended claims.

Claims
  • 1. A prosthetic heart valve, comprising: an expandable inner stent having an inflow end and an outflow end;an expandable outer stent having an atrial end and a ventricular end, the outer stent being secured to and at least partially surrounding the inner stent;a valve assembly disposed within the inner stent, the valve assembly including a cuff and a plurality of leaflets;a tether connector positioned at the inflow end of the inner stent and also along a central longitudinal axis of the inner stent when the inner stent is in an expanded condition; anda tether having a first end and a second end remote from the first end, the first end of the tether being secured to the tether connector so that a length of the tether between the first end and the second end extends along the central longitudinal axis,wherein the plurality of leaflets are positioned relative to the tether such that, in an implanted condition of the prosthetic heart valve, the plurality of leaflets are configured to close around the tether during ventricular systole.
  • 2. The prosthetic heart valve of claim 1, wherein the outflow end of the inner stent is disposed completely between the atrial end and the ventricular end of the outer stent when the inner stent is in the expanded condition and when the outer stent is in an expanded condition.
  • 3. The prosthetic heart valve of claim 1, wherein the ventricular end of the outer stent in an expanded condition has a first diameter and the atrial end of the outer stent in the expanded condition has a second diameter larger than the first diameter.
  • 4. The prosthetic heart valve of claim 1, wherein the inflow end of the inner stent in the expanded condition has a first diameter and the outflow end of the inner stent in the expanded condition has a second diameter larger than the first diameter.
  • 5. The prosthetic heart valve of claim 1, further comprising: a tissue skirt disposed about a luminal surface of the outer stent;a fabric skirt disposed about an abluminal surface of the outer stent; anda mesh cover attached from the atrial end of the outer stent to a portion of the inner stent.
  • 6. The prosthetic heart valve of claim 1, wherein the ventricular end of the outer stent includes a pair of retaining loops.
  • 7. The prosthetic heart valve of claim 6, further comprising a suture coupled to each of the retaining loops for crimping the ventricular end of the outer stent.
  • 8. The prosthetic heart valve of claim 1, further comprising a ring disposed at the ventricular end and on an anterior side of the outer stent.
  • 9. The prosthetic heart valve of claim 8, further comprising a cord attached to the ring and configured to be secured the native anterior leaflet.
  • 10. The prosthetic heart valve of claim 1, wherein the tether connector is positioned adjacent the atrial end of the outer stent.
  • 11. The prosthetic heart valve of claim 1, further comprising an apical pad for holding the tether in a tensioned condition.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of the filing date of U.S. Provisional Patent Application No. 63/052,160 filed on Jul. 15, 2020 the disclosure of which is hereby incorporated herein by reference.

US Referenced Citations (213)
Number Name Date Kind
3657744 Ersek Apr 1972 A
3898701 La Russa Aug 1975 A
4275469 Gabbay Jun 1981 A
4423730 Gabbay Jan 1984 A
4491986 Gabbay Jan 1985 A
4759758 Gabbay Jul 1988 A
4878906 Lindemann et al. Nov 1989 A
4922905 Strecker May 1990 A
4994077 Dobben Feb 1991 A
5078720 Burton et al. Jan 1992 A
5332402 Teitelbaum Jul 1994 A
5411552 Andersen et al. May 1995 A
5415664 Pinchuk May 1995 A
5480423 Ravenscroft et al. Jan 1996 A
5484444 Braunschweiler et al. Jan 1996 A
5702418 Ravenscroft Dec 1997 A
5824041 Lenker et al. Oct 1998 A
5843167 Dwyer et al. Dec 1998 A
5855601 Bessler et al. Jan 1999 A
5924424 Stevens et al. Jul 1999 A
5935163 Gabbay Aug 1999 A
5961549 Nguyen et al. Oct 1999 A
5968068 Dehdashtian et al. Oct 1999 A
5980533 Holman Nov 1999 A
6077297 Robinson et al. Jun 2000 A
6083257 Taylor et al. Jul 2000 A
6090140 Gabbay Jul 2000 A
6214036 Letendre et al. Apr 2001 B1
6264691 Gabbay Jul 2001 B1
6267783 Letendre et al. Jul 2001 B1
6269819 Oz et al. Aug 2001 B1
6306141 Jervis Oct 2001 B1
6332893 Mortier Dec 2001 B1
6368348 Gabbay Apr 2002 B1
6391050 Broome May 2002 B1
6419695 Gabbay Jul 2002 B1
6458153 Bailey et al. Oct 2002 B1
6468299 Stack et al. Oct 2002 B2
6468660 Ogle et al. Oct 2002 B2
6488702 Besselink Dec 2002 B1
6517576 Gabbay Feb 2003 B2
6533810 Hankh et al. Mar 2003 B2
6582464 Gabbay Jun 2003 B2
6610088 Gabbay Aug 2003 B1
6623518 Thompson et al. Sep 2003 B2
6685625 Gabbay Feb 2004 B2
6719789 Cox Apr 2004 B2
6730118 Spenser et al. May 2004 B2
6783556 Gabbay Aug 2004 B1
6790230 Beyersdorf et al. Sep 2004 B2
6797002 Spence Sep 2004 B2
6814746 Thompson et al. Nov 2004 B2
6830584 Seguin Dec 2004 B1
6869444 Gabbay Mar 2005 B2
6893460 Spenser et al. May 2005 B2
6908481 Cribier Jun 2005 B2
7018406 Seguin et al. Mar 2006 B2
7025780 Gabbay Apr 2006 B2
7137184 Schreck Nov 2006 B2
7160322 Gabbay Jan 2007 B2
7247167 Gabbay Jul 2007 B2
7267686 DiMatteo et al. Sep 2007 B2
7311730 Gabbay Dec 2007 B2
7374573 Gabbay May 2008 B2
7381218 Schreck Jun 2008 B2
7452371 Pavcnik et al. Nov 2008 B2
7510572 Gabbay Mar 2009 B2
7524331 Birdsall Apr 2009 B2
RE40816 Taylor et al. Jun 2009 E
7585321 Cribier Sep 2009 B2
7682390 Seguin Mar 2010 B2
7731742 Schlick et al. Jun 2010 B2
7803185 Gabbay Sep 2010 B2
7846203 Cribier Dec 2010 B2
7846204 Letac et al. Dec 2010 B2
7857845 Stacchino et al. Dec 2010 B2
7914569 Nguyen et al. Mar 2011 B2
D648854 Braido Nov 2011 S
D652926 Braido Jan 2012 S
D652927 Braido et al. Jan 2012 S
D653341 Braido et al. Jan 2012 S
D653342 Braido et al. Jan 2012 S
D653343 Ness et al. Jan 2012 S
D654169 Braido Feb 2012 S
D654170 Braido et al. Feb 2012 S
D660432 Braido May 2012 S
D660433 Braido et al. May 2012 S
D660967 Braido et al. May 2012 S
8252051 Chau Aug 2012 B2
D684692 Braido Jun 2013 S
8628571 Hacohen Jan 2014 B1
8840661 Manasse Sep 2014 B2
8840663 Salahieh et al. Sep 2014 B2
9480559 Vidlund Nov 2016 B2
9827092 Vidlund Nov 2017 B2
9895221 Vidlund Feb 2018 B2
10201419 Vidlund Feb 2019 B2
10299917 Morriss May 2019 B2
10463489 Christianson Nov 2019 B2
10470877 Tegels Nov 2019 B2
10492908 Hammer Dec 2019 B2
10610358 Vidlund Apr 2020 B2
10952844 Vidlund Mar 2021 B2
11033389 Solem Jun 2021 B2
11039921 Tegels Jun 2021 B2
11096782 Christianson Aug 2021 B2
11179236 Schankereli Nov 2021 B2
11648108 Liu May 2023 B2
20020036220 Gabbay Mar 2002 A1
20030023303 Palmaz et al. Jan 2003 A1
20030050694 Yang et al. Mar 2003 A1
20030130726 Thorpe et al. Jul 2003 A1
20040049262 Obermiller et al. Mar 2004 A1
20040093075 Kuehne May 2004 A1
20040210304 Seguin et al. Oct 2004 A1
20040225354 Allen Nov 2004 A1
20050075727 Wheatley Apr 2005 A1
20050096726 Sequin et al. May 2005 A1
20050137695 Salahieh Jun 2005 A1
20050137697 Salahieh et al. Jun 2005 A1
20050240200 Bergheim Oct 2005 A1
20050256566 Gabbay Nov 2005 A1
20060008497 Gabbay Jan 2006 A1
20060074484 Huber Apr 2006 A1
20060106415 Gabbay May 2006 A1
20060122692 Gilad et al. Jun 2006 A1
20060142848 Gabbay Jun 2006 A1
20060149360 Schwammenthal et al. Jul 2006 A1
20060167468 Gabbay Jul 2006 A1
20060173532 Flagle et al. Aug 2006 A1
20060178740 Stacchino et al. Aug 2006 A1
20060195180 Kheradvar et al. Aug 2006 A1
20060206202 Bonhoeffer et al. Sep 2006 A1
20060241744 Beith Oct 2006 A1
20060241745 Solem Oct 2006 A1
20060259120 Vongphakdy et al. Nov 2006 A1
20060259137 Artof et al. Nov 2006 A1
20060265056 Nguyen et al. Nov 2006 A1
20060276813 Greenberg Dec 2006 A1
20070010876 Salahieh et al. Jan 2007 A1
20070027534 Bergheim et al. Feb 2007 A1
20070043435 Seguin et al. Feb 2007 A1
20070055358 Krolik et al. Mar 2007 A1
20070067029 Gabbay Mar 2007 A1
20070073391 Bourang et al. Mar 2007 A1
20070088431 Bourang et al. Apr 2007 A1
20070093890 Eliasen et al. Apr 2007 A1
20070100435 Case et al. May 2007 A1
20070112422 Dehdashtian May 2007 A1
20070118210 Pinchuk May 2007 A1
20070162100 Gabbay Jul 2007 A1
20070168013 Douglas Jul 2007 A1
20070203575 Forster et al. Aug 2007 A1
20070213813 Von Segesser et al. Sep 2007 A1
20070233228 Eberhardt et al. Oct 2007 A1
20070239271 Nguyen Oct 2007 A1
20070244545 Birdsall et al. Oct 2007 A1
20070244552 Salahieh et al. Oct 2007 A1
20070270943 Solem Nov 2007 A1
20070288087 Fearnot et al. Dec 2007 A1
20080021552 Gabbay Jan 2008 A1
20080039934 Styrc Feb 2008 A1
20080071369 Tuval et al. Mar 2008 A1
20080082164 Friedman Apr 2008 A1
20080097595 Gabbay Apr 2008 A1
20080114452 Gabbay May 2008 A1
20080125853 Bailey et al. May 2008 A1
20080140189 Nguyen et al. Jun 2008 A1
20080147182 Righini et al. Jun 2008 A1
20080147183 Styrc Jun 2008 A1
20080154355 Benichou et al. Jun 2008 A1
20080154356 Obermiller et al. Jun 2008 A1
20080243245 Thambar Oct 2008 A1
20080255662 Stacchino et al. Oct 2008 A1
20080262602 Wilk et al. Oct 2008 A1
20080269879 Sathe et al. Oct 2008 A1
20090054975 del Nido et al. Feb 2009 A1
20090099653 Suri et al. Apr 2009 A1
20090112309 Jaramillo et al. Apr 2009 A1
20090138079 Tuval et al. May 2009 A1
20100004740 Seguin et al. Jan 2010 A1
20100036484 Hariton et al. Feb 2010 A1
20100049306 House et al. Feb 2010 A1
20100087907 Lattouf Apr 2010 A1
20100131055 Case et al. May 2010 A1
20100168778 Braido Jul 2010 A1
20100168839 Braido et al. Jul 2010 A1
20100185277 Braido et al. Jul 2010 A1
20100191326 Alkhatib Jul 2010 A1
20100204781 Alkhatib Aug 2010 A1
20100204785 Alkhatib Aug 2010 A1
20100217382 Chau Aug 2010 A1
20100249911 Alkhatib Sep 2010 A1
20100249923 Alkhatib et al. Sep 2010 A1
20100286768 Alkhatib Nov 2010 A1
20100298931 Quadri et al. Nov 2010 A1
20110029072 Gabbay Feb 2011 A1
20110224678 Gabbay Sep 2011 A1
20120303116 Gorman, III et al. Nov 2012 A1
20130079873 Migliazza Mar 2013 A1
20130172978 Vidlund et al. Jul 2013 A1
20130184811 Rowe Jul 2013 A1
20140296969 Tegels Oct 2014 A1
20140296975 Tegels Oct 2014 A1
20140358224 Tegels Dec 2014 A1
20160235525 Rothstein et al. Aug 2016 A1
20170128209 Morriss et al. May 2017 A1
20170312078 Krivoruchko Nov 2017 A1
20170319333 Tegels Nov 2017 A1
20180014932 Hammer Jan 2018 A1
20190183642 Tegels Jun 2019 A1
20190269839 Wilson Sep 2019 A1
20210030537 Tegels Feb 2021 A1
Foreign Referenced Citations (40)
Number Date Country
19857887 Jul 2000 DE
10121210 Nov 2005 DE
102005003632 Aug 2006 DE
202008009610 Dec 2008 DE
0850607 Jul 1998 EP
1000590 May 2000 EP
1129744 Sep 2001 EP
1157673 Nov 2001 EP
1360942 Nov 2003 EP
1584306 Oct 2005 EP
1598031 Nov 2005 EP
1926455 Jun 2008 EP
2850008 Jul 2004 FR
2847800 Oct 2005 FR
9117720 Nov 1991 WO
9716133 May 1997 WO
9832412 Jul 1998 WO
9913801 Mar 1999 WO
2001028459 Apr 2001 WO
2001049213 Jul 2001 WO
0154625 Aug 2001 WO
0156500 Aug 2001 WO
0176510 Oct 2001 WO
0236048 May 2002 WO
0247575 Jun 2002 WO
02067782 Sep 2002 WO
03047468 Jun 2003 WO
2005070343 Aug 2005 WO
06073626 Jul 2006 WO
2007071436 Jun 2007 WO
08070797 Jun 2008 WO
2010008548 Jan 2010 WO
2010008549 Jan 2010 WO
10051025 May 2010 WO
10087975 Aug 2010 WO
2010096176 Aug 2010 WO
2010098857 Sep 2010 WO
WO-2013028387 Feb 2013 WO
WO-2018218121 Nov 2018 WO
WO-2019057185 Mar 2019 WO
Non-Patent Literature Citations (17)
Entry
“Catheter-Implanted Prosthetic Heart Valves: Transluminal Catheter Implantation of a New Expandable Artificial Heart Valve in the Descending Thoracic Aorta In Isolated Vessels and Closed Chest Pigs”, Knudsen et al., The International Journal of Artificial Organs, vol. 16, No. 5, May 1993, pp. 253-262.
“Direct-Access Valve Replacement”, Christoph H. Huber, et al., Journal of the American College of Cardiology, vol. 46, No. 2, (Jul. 19, 2005).
“Minimally invasive cardiac surgery”, M. J. Mack, Surgical Endoscopy, 2006, 20:S488-S492, DOI: 10.1007/s00464-006-0110-8 (presented Mar. 23, 2006).
“Percutaneous Aortic Valve Implantation Retrograde From the Femoral Artery”, John G. Webb et al., Circulation, 2006; 113:842-850 (Feb. 6, 2006).
“Percutaneous Aortic Valve Replacement: Resection Before Implantation”, Quaden, Rene et al., European J. of Cardio-Thoracic Surgery, vol. 27, No. 5, May 2005, pp. 836-840.
“Transapical aortic valve implantation: an animal feasibility study”; Todd M. Dewey et al., The annals of thoracic surgery 2006; 82: 110-6 (Feb. 13, 2006).
“Transapical Transcatheter Aortic Valve Implantation in Humans”, Samuel V. Lichtenstein et al., Circulation. 2006; 114: 591-596 (Jul. 31, 2006).
“Transluminal Aortic Valve Placement. A Feasability Study with a Newly Designed Collapsible Aortic Valve”, Moazami et al., ASAIO Journal, vol. 42, No. 5, 1996, pp. M381-M385.
“Transluminal Catheter Implanted Prosthetic Heart Valves”, Andersen, H. R., International Journal of Angiology, vol. 7, No. 2, Mar. 1998, pp. 102-106.
“Transluminal Implantation of Artificial Heart Valves”, Andersen, H. R., et al., European Heart Journal, vol. 13, No. 5, May 1992, pp. 704-708.
Closed Heart Surgery: Back to the Future, Samuel V. Lichtenstein, The Journal of Thoracic and Cardiovascular Surgery, vol. 131, No. 5, May 2006, pp. 941-943.
Is It Reasonable to Treat All Calcified Stenotic Aortic Valves With a Valved Stent?, 579-584, Zegdi, Rachid, MD, PhD et al., J. of the American College of Cardiology, vol. 51, No. 5, Feb. 5, 2008.
Ruiz, Carlos, Overview of PRE-CE Mark Transcatheter Aortic Valve Technologies, Euro PCR—dated May 25, 2010?
Transapical Approach for Sutureless Stent-Fixed Aortic Valve Implantation: Experimental Results, Th. Walther et al., European Journal of Cardio-Thoracic Surgery, vol. 29, No. 5, May 2006, pp. 703-708.
Transcatheter Valve Repair, Hijazi et al., CRC Press, Jan. 2006, pp. 165-186.
U.S. Appl. No. 29/375,243, filed Sep. 20, 2010—Braido, et al., U.S. Appl. No. 29/375,243, filed Sep. 20, 2010, titled “Surgical Stent Assembly”.
International Search Report for PCT/US2021/041243 mailed Oct. 28, 2021 (3 pages).
Related Publications (1)
Number Date Country
20220015899 A1 Jan 2022 US
Provisional Applications (1)
Number Date Country
63052160 Jul 2020 US